RavenQuest BioMed Inc.
RVVQF
$0.00
$0.000.00%
| 07/31/2019 | 04/30/2019 | 01/31/2019 | 10/31/2018 | 07/31/2018 | |
|---|---|---|---|---|---|
| Revenue | -3.82% | -29.96% | 27.49% | 1,000.44% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.82% | -29.96% | 27.49% | 1,000.44% | -- |
| Cost of Revenue | 17.61% | -27.34% | -173.09% | 358.31% | -- |
| Gross Profit | -14.84% | -31.50% | 289.62% | 5,293.16% | -- |
| SG&A Expenses | 34.79% | 98.13% | 538.82% | 1,760.59% | 3,177.14% |
| Depreciation & Amortization | 8,913.41% | 55,241.86% | 168,375.00% | 721,850.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.01% | 137.33% | 513.73% | 1,833.59% | 3,448.67% |
| Operating Income | -96.24% | -186.74% | -728.97% | -1,994.04% | -2,802.34% |
| Income Before Tax | -205.09% | -314.42% | -647.10% | -811.64% | -2,255.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -199.70% | -307.13% | -634.10% | -794.73% | -2,255.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -199.70% | -307.13% | -634.13% | -794.72% | -2,255.54% |
| EBIT | -96.24% | -186.74% | -728.97% | -1,994.04% | -2,802.34% |
| EBITDA | -41.66% | -128.82% | -666.04% | -2,703.20% | -37,481.56% |
| EPS Basic | -83.32% | -115.22% | -215.23% | -251.31% | -900.83% |
| Normalized Basic EPS | -88.78% | -157.69% | -472.57% | -798.10% | -965.22% |
| EPS Diluted | -83.32% | -115.22% | -215.23% | -251.31% | -900.83% |
| Normalized Diluted EPS | -88.78% | -157.69% | -472.57% | -798.10% | -965.22% |
| Average Basic Shares Outstanding | 53.44% | 88.02% | 133.72% | 180.32% | 156.71% |
| Average Diluted Shares Outstanding | 53.44% | 88.02% | 133.72% | 180.32% | 156.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
